COMPANY

Zumutor Biologics

Keywords: antibody oncology cancer Non Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Pancreas Adenocarcinoma Biliary Tract Cancer Prostate Cancer Urothelial Carcinoma Colorectal Cancer Triple Negative Breast Cancer High Grade Ovarian Serous Adenocarcinoma Diffuse Large B Cell Lymphoma Renal Cell Cancer Metastatic ZM008

Location: Woburn, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

May 22, 2024 Trial start 1: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

2026-12 (ESTIMATED) · 1 · This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors · NCT06451497

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06451497	This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors	1	Recruiting	May 22, 2024	2026-12 (estimated)